DPP4i sitagliptin, saxagliptin, and linagliptin reduce tau phosphorylation and Aβ42 levels in the cortex and CA3 area from 3xTg-AD mice [218, 219], with linagliptin also decreasing Aβ deposits [219]. This evidence concerns the gene MAPT and Alzheimer disease.